Objectives There are few comparative data for tumor necrosis factor inhibitors in patients
with rheumatoid arthritis (RA). Methods Historical data for reference product/biosimilar …

Rheumatoid arthritis (RA) is a chronic inflammatory systemic disease characterized by
persistent joint synovial inflammation and swelling, leading to cartilage damage and bone …

Objective The aim of this study was to describe treatment patterns in RA, including the
frequency and reasons for switching or stopping biologic and targeted synthetic DMARDs …

Infliximab (IFX) has contributed to the treatment of several chronic inflammatory diseases,
including Crohn's disease (CD), ulcerative colitis (UC), psoriasis (Pso), and rheumatoid …

Although biologics have their own characteristics, there are no clear criteria for selecting
them to treat the patients with rheumatoid arthritis. To assist in selecting biologics, we …

The loss of patentability of many originator biologics has led to the rapid introduction of
biosimilar agents. The anticipated economic benefit of introducing such agent has been …

The survival rate of cardiac arrest patients is less than 10%; therefore, development of a
therapeutic strategy that improves their prognosis is necessary. Herein, we searched data …

Objectives: The objective of this study is to compare the effectiveness of biological disease-
modifying antirheumatic drugs (bDMARDs) by analyzing claims data of 13 Japanese …

Objectives To describe the status of using biological Disease Modifying Anti Rheumatic
Drugs (bDMARDs) to treat rheumatoid arthritis (RA) and related factors. In addition, the study …

Objective To assess the clinical and structural impact at 2 years of progressively spacing
tocilizumab (TCZ) or abatacept (ABA) injections versus maintenance at full dose in …